81 FR 29142 - Schedules of Controlled Substances: Placement of UR-144, XLR11, and AKB48 into Schedule I
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 81, Issue 91 (May 11, 2016)
Drug Enforcement Administration
Federal Register Volume 81, Issue 91 (May 11, 2016)
| Page Range | 29142-29145 | |
| FR Document | 2016-11204 |
[Federal Register Volume 81, Number 91 (Wednesday, May 11, 2016)] [Rules and Regulations] [Pages 29142-29145] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-11204] [[Page 29142]] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-417] Schedules of Controlled Substances: Placement of UR-144, XLR11, and AKB48 into Schedule I AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final rule. ----------------------------------------------------------------------- SUMMARY: With the issuance of this final rule, the Drug Enforcement Administration places (1-pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11), and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48), including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into schedule I of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle UR-144, XLR11, or AKB48. DATES: Effective: May 11, 2016. FOR FURTHER INFORMATION CONTACT: Barbara J. Boockholdt, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812. SUPPLEMENTARY INFORMATION: Legal Authority The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III are referred to as the ``Controlled Substances Act'' and the ``Controlled Substances Import and Export Act,'' respectively, and are collectively referred to as the ``Controlled Substances Act'' or the ``CSA'' for the purposes of this action. 21 U.S.C. 801-971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while ensuring an adequate supply is available for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Under the CSA, each controlled substance is classified into one of five schedules based upon its potential for abuse, its currently accepted medical use in treatment in the United States, and the degree of dependence the substance may cause. 21 U.S.C. 812. The initial schedules of controlled substances established by Congress are found at 21 U.S.C. 812(c) and the current list of scheduled substances is published at 21 CFR part 1308. 21 U.S.C. 812(a). Pursuant to 21 U.S.C. 811(a)(1), the Attorney General may, by rule, ``add to such a schedule or transfer between such schedules any drug or other substance if he . . . finds that such drug or other substance has a potential for abuse, and . . . makes with respect to such drug or other substance the findings prescribed by subsection (b) of section 812 of this title for the schedule in which such drug is to be placed . . . .'' The Attorney General has delegated scheduling authority under 21 U.S.C. 811 to the Administrator of the DEA, 28 CFR 0.100, who in turn has redelegated that authority to the Deputy Administrator of the DEA, 28 CFR part 0, appendix to subpart R. The CSA provides that proceedings for the issuance, amendment, or repeal of the scheduling of any drug or other substance may be initiated by the Attorney General (1) on her own motion; (2) at the request of the Secretary of the Department of Health and Human Services (HHS); \1\ or (3) on the petition of any interested party. 21 U.S.C. 811(a). This action was initiated by the former DEA Administrator on her own motion and is supported by a recommendation from the Assistant Secretary of the HHS and an evaluation of all other relevant data by the DEA. This action imposes the regulatory controls and administrative, civil, and criminal sanctions of schedule I controlled substances on any person who handles, or proposes to handle, UR-144, XLR11, or AKB48. --------------------------------------------------------------------------- \1\ As set forth in a memorandum of understanding entered into by the Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the HHS in carrying out the Secretary's scheduling responsibilities under the CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations. 58 FR 35460, July 1, 1993. Accordingly, all subsequent references to ``Secretary'' have been replaced with ``Assistant Secretary.'' --------------------------------------------------------------------------- Background On April 12, 2013, the DEA published a notice of intent to temporarily place (1-pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11), and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48) into schedule I pursuant to the temporary scheduling provisions of the CSA. 78 FR 21858. On May 16, 2013, the DEA published a final order amending 21 CFR 1308.11(h) to temporarily place these three synthetic cannabinoids into schedule I of the CSA pursuant to the temporary scheduling provisions of 21 U.S.C. 811(h). 78 FR 28735. That final order was effective on the date of publication, and was based on findings by the DEA that the temporary scheduling of these three synthetic cannabinoids was necessary to avoid an imminent hazard to the public safety pursuant to 21 U.S.C. 811(h)(1). Section 201(h)(2) of the CSA requires that the temporary control of these substances expire two years from the effective date of the scheduling order, or on May 15, 2015. 21 U.S.C. 811(h)(2). However, the CSA also provides that the temporary scheduling may be extended for up to one year during the pendency of proceedings under 21 U.S.C. 811(a)(1). Id. Accordingly, on May 14, 2015, the DEA published a notice of proposed rulemaking (NPRM) to permanently control UR-144, XLR11, and AKB48 in schedule I of the CSA. 80 FR 27611. Specifically, the DEA proposed to add these substances to 21 CFR 1308.11(g), cannabimimetic agents. On May 15, 2015, the DEA extended the temporary scheduling of UR-144, XLR11, and AKB48 by one year, until May 15, 2016. 80 FR 27854. On March 22, 2016, the DEA published a corrected notice of proposed rulemaking, proposing the placement of these substances as hallucinogenic substances under 21 CFR 1308.11(d), and providing an opportunity to comment on this proposed change. 81 FR 15188. [[Page 29143]] DEA and HHS Eight Factor Analyses On May 11, 2015, the HHS provided the DEA with three scientific and medical evaluation documents prepared by the FDA entitled ``Basis for the recommendation to place 1-pentyl-1H-indol-3-yl-2,2,3,3- tetramethylcyclopropyl methanone (UR-144) and its salts in Schedule 1 of the Controlled Substances Act (CSA);'' ``Basis for the recommendation to place 1-(5-fluoro-pentyl)-1H-indol-3-yl 2,2,3,3- tetramethylcyclopropyl methanone (XLR11) and its salts in Schedule 1 of the Controlled Substances Act (CSA);'' and ``Basis for the recommendation to place (N-(1-adamantyl)-1-pentyl-1H-indazole-3- carboxamide) (AKB48; APINACA) and its salts in Schedule 1 of the Controlled Substances Act (CSA).'' After considering the eight factors in 21 U.S.C. 811(c), including consideration of each substance's abuse potential, legitimate medical use, and dependence liability, the Assistant Secretary of the HHS recommended that UR-144, XLR11, and AKB48 be controlled in schedule I of the CSA. In response, the DEA conducted its own eightfactor analysis of UR-144, XLR11, and AKB48. The DEA and HHS analyses are available in their entirety in the public docket for this rule (DEA-2015-0007/agency Docket Number DEA-417) at http://www.regulations.gov under ``Supporting Documents.'' Determination To Schedule UR-144, XLR11, and AKB48 After a review of the available data, including the scientific and medical evaluations and the scheduling recommendations from the HHS, the DEA published an NPRM entitled ``Schedules of Controlled Substances: Placement of UR-144, XLR11, and AKB48 into Schedule I,'' proposing to control UR-144, XLR11, and AKB48 in schedule I of the CSA. 80 FR 27611, May 14, 2015. The proposed rule provided an opportunity for interested persons to file a request for hearing in accordance with the DEA regulations on or before June 15, 2015. No requests for such a hearing were received by the DEA. The NPRM also provided an opportunity for interested persons to submit written comments on the proposal on or before June 15, 2015. Comments Received The DEA received three comments on the proposed rule to control UR- 144, XLR11, and AKB48 in schedule I of the CSA. One commenter stated that the ``longwinded and unnecessarily difficult names of the chemical substances mentioned'' were offensive and that they should be changed ``in the name of a truly transparent government.'' A second commenter questioned the safety of methadone, and the third commenter opposed the control of UR-144, XLR11, and AKB48. Two comments were received in response to the publication of the NPRM correction, for which comments were to be limited to addressing the change in the proposed placement in the CFR for the substances as hallucinogenic substances rather than cannabimimetic agents Both comments addressed whether or not these substances should be scheduled, with one commenter supporting scheduling and the other opposing. Thus, both comments were outside the scope for which comments were being accepted. Comments Received in Response to NPRM. Request to Shorten Chemical Names. One commenter stated that the chemical names for UR-144, XLR11, and AKB48 were unnecessarily difficult to understand and requested they be shortened. DEA Response: In order to ensure the public is aware of the specific substances that were proposed to be controlled, and are controlled, as schedule I substances, the DEA used both the standard chemical names for UR-144, XLR11, and AKB48 and the common street level names that correspond to each substance. All names known by the DEA for UR-144, XLR11, and AKB48 were provided in the NPRM, the NPRM correction, and in this final rule. In addition, to prevent any confusion with nomenclature or other references to these substances, the DEA also used shortened names for these substances, including UR- 144, XLR11, 5-fluoro-UR-144, AKB48, and APINACA. Each of the names provided in the NPRM, the NPRM correction, and this final rule are commonly accepted identifiers for the three substances. Comment Regarding Methadone. One commenter stated that methadone is very dangerous to use, especially with the consumption of alcohol. DEA Response: Methadone is a schedule II synthetic opioid and is not affected by this rule. Request Not to Control UR-144, XLR11, and AKB48. One commenter opposed controlling UR-144, XLR11, and AKB48 stating ``there is no reason to have this law.'' DEA Response: As outlined in detail in the HHS and DEA eight-factor analyses, there is substantial evidence to support control of UR-144, XLR11, and AKB48 in schedule I of the CSA. The use of UR-144, XLR11, and/or AKB48 has been linked to serious adverse effects including vomiting, nausea, anxiety, agitation, seizures, hallucinations, tachycardia, and stroke, which require visits to emergency facilities. In addition to the serious adverse effects, the misuse and abuse of UR-144, XLR11, and/or AKB48 has been shown to result in death. As reported by the National Forensic Laboratory Information System (NFLIS), there have been over 46,000 reports for UR- 144, XLR11, and AKB48 since 2011 in at least 44 states. As determined by the HHS, there is no accepted medical use for UR-144, XLR11, and AKB48. Scheduling Conclusion After consideration of the relevant matter presented as a result of public comment, the scientific and medical evaluations and accompanying recommendations of the HHS, and its own eight-factor analyses, the DEA finds that these facts and all other relevant data constitute substantial evidence of potential for abuse of UR-144, XLR11, and AKB48. As such, the DEA is permanently scheduling UR-144, XLR11, and AKB48 as controlled substances under the CSA.\2\ --------------------------------------------------------------------------- \2\ UR-144, XLR11, and AKB48 were initially proposed to be scheduled under Sec. 1308.11(g). However, they do not meet the structural requirement for ``cannabimimetic agents.'' Consistent with the analysis set forth in the DEA's 8-factor analysis, on March 22, 2016, the DEA published a corrected notice of proposed rulemaking, with opportunity for comment, proposing the placement of these substances as hallucinogenic substances under 21 CFR 1308.11(d). 81 FR 15188. The substances are being placed under Sec. 1308.11(d), hallucinogenic substances, under this final rule. --------------------------------------------------------------------------- Determination of Appropriate Schedule The CSA establishes five schedules of controlled substances known as schedules I, II, III, IV, and V. The CSA also outlines the findings required to place a drug or other substance in any particular schedule. 21 U.S.C. 812(b). After consideration of the analyses and recommendations of the Assistant Secretary for HHS and review of all other available data, the Administrator of the DEA, pursuant to 21 U.S.C. 811(a) and 21 U.S.C. 812(b)(1), finds that: (1) (1-pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11), and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48) have a high potential for abuse that is comparable to other schedule I substances such as delta-9- [[Page 29144]] tetrahydrocannabinol ([Delta]\9\-THC) and JWH-018; (2) (1-pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11), and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48) have no currently accepted medical use in treatment in the United States; and (3) There is a lack of accepted safety for use of (1-pentyl-1H- indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5- fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11) and N-(1-adamantyl)-1-pentyl-1H-indazole-3- carboxamide (APINACA, AKB48) under medical supervision. Based on these findings, the Administrator of the DEA concludes that (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11), and N-(1- adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48) including their salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible, warrant control in schedule I of the CSA. 21 U.S.C. 812(b)(1). Requirements for Handling UR-144, XLR11, and AKB48 UR-144, XLR11, and AKB48 are currently scheduled on a temporary basis in schedule I \3\ and therefore continue to be subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, reverse distribution, importation, exportation, engagement in research and conduct of instructional activities or chemical analysis, and possession of schedule I controlled substances, including those listed below. These controls will continue on a permanent basis: --------------------------------------------------------------------------- \3\ UR-144, XLR11, and AKB48 are currently subject to schedule I controls on a temporary basis, pursuant to 21 U.S.C. 811(h). 80 FR 27854, May 15, 2016. --------------------------------------------------------------------------- 1. Registration. Any person who handles (manufactures, distributes, reverse distributes, imports, exports, engages in research, or conducts instructional activities or chemical analysis with, or possesses) UR- 144, XLR11, or AKB48, or who desires to handle UR-144, XLR11, or AKB48 must be registered with the DEA to conduct such activities pursuant to 21 U.S.C. 822, 823, 957, and 958, and in accordance with 21 CFR parts 1301 and 1312. 2. Disposal of Stocks. UR-144, XLR11, and AKB 48 must be disposed of in accordance with 21 CFR part 1317, in addition to all other applicable federal, state, local, and tribal laws. 3. Security. UR-144, XLR11, and AKB48 continue to be subject to schedule I security requirements and must be handled and stored pursuant to 21 U.S.C. 821, 823, and 871(b), and in accordance with 21 CFR 1301.71-1301.93. 4. Labeling and Packaging. All labels, labeling, and packaging for commercial containers of UR-144, XLR11, and AKB48 must comply with 21 U.S.C. 825 and 958(e), and be in accordance with 21 CFR part 1302. 5. Quota. Only registered manufacturers are permitted to manufacture UR-144, XLR11, or AKB48 in accordance with a quota assigned pursuant to 21 U.S.C. 826 and in accordance with 21 CFR part 1303. 6. Inventory. Every DEA registrant required to keep records and who possesses any quantity of UR-144, XLR11, or AKB48 is required to maintain an inventory of all stocks of UR-144, XLR11, and/or AKB48 on hand, pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR 1304.03, 1304.04, and 1304.11. 7. Records and Reports. Every DEA registrant must maintain records and submit reports pursuant to 21 U.S.C. 827 and 958, and in accordance with 21 CFR parts 1304, 1312, and 1317. Manufacturers and distributors must submit reports regarding UR-144, XLR11, and/or AKB48 to the Automation of Reports and Consolidated Order System (ARCOS) pursuant to 21 U.S.C. 827 and in accordance with 21 CFR 1304 and 1312. 8. Order Forms. Every DEA registrant who distributes UR-144, XLR11, and/or AKB48 must continue to comply with the order form requirements, pursuant to 21 U.S.C. 828 and 21 CFR part 1305. 9. Importation and Exportation. All importation and exportation of UR-144, XLR11, and AKB48 must be in compliance with 21 U.S.C. 952, 953, 957, and 958, and in accordance with 21 CFR part 1312. 10. Liability. Any activity involving UR-144, XLR11, or AKB48 not authorized by, or in violation of, the CSA or its implementing regulations continues to be unlawful, and may subject the person to administrative, civil, and/or criminal sanctions. Regulatory Analyses Administrative Procedure Act The Administrative Procedure Act (APA) generally requires that rules enacted in accordance with the procedures of 5 U.S.C. 553 to be effective not less than 30 days after publication of the proposed rule. 5 U.S.C. 553(d). However, the APA provides three exceptions for when an agency may make a rule effective sooner than 30 days after publication, including if the agency finds for good cause why the rule should be effective sooner and publishes those reasons with the rule. 5 U.S.C. 553(d)(3). The DEA finds that there is good cause for this scheduling action to be immediately effective upon publication. A delay in the effective date is unnecessary and contrary to the public interest. It is unnecessary because UR-144, XLR11, and AKB48 are already controlled under 21 U.S.C. 811(h). Additionally, a delay in the effective date could potentially temporarily eliminate these substances from being controlled, thereby resulting in an imminent hazard to the public safety. As noted above, the use of UR-144, XLR11, and/or AKB48 has been linked to serious adverse effects including vomiting, nausea, anxiety, agitation, seizures, hallucinations, tachycardia, and stroke, which require visits to emergency facilities. In addition to the serious adverse effects, the misuse and abuse of UR-144, XLR11, and/or AKB48 has been shown to result in death. Executive Orders 12866 and 13563, Regulatory Planning and Review, and 13563, Improving Regulation and Regulatory Review In accordance with 21 U.S.C. 811(a), this scheduling action is subject to formal rulemaking procedures done ``on the record after opportunity for a hearing,'' which are conducted pursuant to the provisions of 5 U.S.C. 556 and 557. The CSA sets forth the criteria for scheduling a drug or other substance. Such actions are exempt from review by the Office of Management and Budget (OMB) pursuant to section 3(d)(1) of Executive Order 12866 and the principles reaffirmed in Executive Order 13563. Executive Order 12988, Civil Justice Reform This regulation meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 to eliminate drafting errors and ambiguity, minimize litigation, provide a clear legal standard for affected conduct, and [[Page 29145]] promote simplification and burden reduction. Executive Order 13132, Federalism This rulemaking does not have federalism implications warranting the application of Executive Order 13132. The proposed rule does not have substantial direct effects on the States, on the relationship between the national government and the States, or the distribution of power and responsibilities among the various levels of government. Executive Order 13175, Consultation and Coordination With Indian Tribal Governments This rule does not have tribal implications warranting the application of Executive Order 13175. It does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes. Regulatory Flexibility Act The Administrator, in accordance with the Regulatory Flexibility Act (RFA), 5 U.S.C. 601-602, has reviewed this final rule and by approving it certifies that it will not have a significant economic impact on a substantial number of small entities. On May 16, 2013, the DEA published a final order amending 21 CFR 1308.11(h) to temporarily place these three synthetic cannabinoids into schedule I of the CSA pursuant to the temporary scheduling provisions of 21 U.S.C. 811(h). 78 FR 28735. On May 15, 2015, the DEA published a final order extending the temporary placement of these substances in schedule I of the CSA for up to one year pursuant to 21 U.S.C. 811(h)(2). 80 FR 27854. Accordingly, all entities that currently handle or plan to handle these synthetic cannabinoids are estimated to have already established and implemented the systems and processes required to handle UR-144, XLR11, and AKB48. Therefore, the DEA anticipates that this rule will impose minimal or no economic impact on businesses that currently handle UR- 144, XLR11, or AKB48 for lawful purposes. This estimate applies to entities large and small. Accordingly, the DEA has concluded that this rule will not have a significant effect on a substantial number of small entities. Unfunded Mandates Reform Act of 1995 On the basis of information contained in the ``Regulatory Flexibility Act'' section above, the DEA has determined and certifies pursuant to the Unfunded Mandates Reform Act (UMRA) of 1995, 2 U.S.C. 1501 et seq., that this action will not result in any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted for inflation) in any one year. Therefore, neither a Small Government Agency Plan nor any other action is required under provisions of the UMRA of 1995. Paperwork Reduction Act of 1995 This action does not impose a new collection of information under the Paperwork Reduction Act of 1995. 44 U.S.C. 3501-3521. This action would not impose recordkeeping or reporting requirements on State or local governments, individuals, businesses, or organizations. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Congressional Review Act This rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act (CRA)). This rule will not result in: ``an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of U.S.-based companies to compete with foreign based companies in domestic and export markets.'' However, pursuant to the CRA, the DEA has submitted a copy of this final rule to both Houses of Congress and to the Comptroller General. List of Subjects in 21 CFR Part 1308 Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements. For the reasons set out above, 21 CFR part 1308 is amended as follows: PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES 0 1. The authority citation for 21 CFR part 1308 continues to read as follows: Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted. 0 2. In Sec. 1308.11: 0 a. Add paragraphs (d) (48) through (50); and 0 b. Remove paragraphs (h)(1) through (3) and redesignate paragraphs (h)(4) through (25) as paragraphs (h)(1) through (22), respectively. The additions read as follows: Sec. 1308.11 Schedule I. * * * * * (d) * * * (48) (1-pentyl-1H-indol-3-yl)(2,2,3,3- (7144) tetramethylcyclopropyl)methanone (UR-144)................... (49) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- (7011) tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11)... (50) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (7048) (APINACA, AKB48)............................................ * * * * * Dated: May 6, 2016. Chuck Rosenberg, Acting Administrator. [FR Doc. 2016-11204 Filed 5-10-16; 8:45 am] BILLING CODE 4410-09-P
![29142 Federal Register / Vol. 81, No. 91 / Wednesday, May 11, 2016 / Rules and Regulations
DEPARTMENT OF JUSTICE purposes of this action. 21 U.S.C. 801– the petition of any interested party. 21
971. The DEA publishes the U.S.C. 811(a). This action was initiated
Drug Enforcement Administration implementing regulations for these by the former DEA Administrator on her
statutes in title 21 of the Code of Federal own motion and is supported by a
21 CFR Part 1308 Regulations (CFR), chapter II. recommendation from the Assistant
[Docket No. DEA–417]
The CSA and its implementing Secretary of the HHS and an evaluation
regulations are designed to prevent, of all other relevant data by the DEA.
Schedules of Controlled Substances: detect, and eliminate the diversion of This action imposes the regulatory
Placement of UR-144, XLR11, and controlled substances and listed controls and administrative, civil, and
AKB48 into Schedule I chemicals into the illicit market while criminal sanctions of schedule I
ensuring an adequate supply is available controlled substances on any person
AGENCY: Drug Enforcement for the legitimate medical, scientific, who handles, or proposes to handle,
Administration, Department of Justice. research, and industrial needs of the UR–144, XLR11, or AKB48.
ACTION: Final rule. United States. Controlled substances Background
have the potential for abuse and
SUMMARY: With the issuance of this final dependence and are controlled to On April 12, 2013, the DEA published
rule, the Drug Enforcement protect the public health and safety. a notice of intent to temporarily place
Administration places (1-pentyl-1H- Under the CSA, each controlled (1-pentyl-1H-indol-3-yl)(2,2,3,3-
indol-3-yl)(2,2,3,3- substance is classified into one of five tetramethylcyclopropyl)methanone (UR-
tetramethylcyclopropyl)methanone (UR- schedules based upon its potential for 144), [1-(5-fluoro-pentyl)-1H-indol-3-
144), [1-(5-fluoro-pentyl)-1H-indol-3- abuse, its currently accepted medical yl](2,2,3,3-
yl](2,2,3,3- use in treatment in the United States, tetramethylcyclopropyl)methanone (5-
tetramethylcyclopropyl)methanone (5- and the degree of dependence the fluoro-UR-144, XLR11), and N-(1-
fluoro-UR-144, XLR11), and N-(1- substance may cause. 21 U.S.C. 812. The adamantyl)-1-pentyl-1H-indazole-3-
adamantyl)-1-pentyl-1H-indazole-3- initial schedules of controlled carboxamide (APINACA, AKB48) into
carboxamide (APINACA, AKB48), substances established by Congress are schedule I pursuant to the temporary
including their salts, isomers, and salts found at 21 U.S.C. 812(c) and the scheduling provisions of the CSA. 78 FR
of isomers whenever the existence of current list of scheduled substances is 21858. On May 16, 2013, the DEA
such salts, isomers, and salts of isomers published at 21 CFR part 1308. 21 published a final order amending 21
is possible, into schedule I of the U.S.C. 812(a). CFR 1308.11(h) to temporarily place
Controlled Substances Act. This Pursuant to 21 U.S.C. 811(a)(1), the these three synthetic cannabinoids into
scheduling action is pursuant to the Attorney General may, by rule, ‘‘add to schedule I of the CSA pursuant to the
Controlled Substances Act which such a schedule or transfer between temporary scheduling provisions of 21
requires that such actions be made on such schedules any drug or other U.S.C. 811(h). 78 FR 28735. That final
the record after opportunity for a substance if he . . . finds that such drug order was effective on the date of
hearing through formal rulemaking. or other substance has a potential for publication, and was based on findings
This action imposes the regulatory abuse, and . . . makes with respect to by the DEA that the temporary
controls and administrative, civil, and such drug or other substance the scheduling of these three synthetic
criminal sanctions applicable to findings prescribed by subsection (b) of cannabinoids was necessary to avoid an
schedule I controlled substances on section 812 of this title for the schedule imminent hazard to the public safety
persons who handle (manufacture, in which such drug is to be placed . . . pursuant to 21 U.S.C. 811(h)(1). Section
distribute, reverse distribute, import, 201(h)(2) of the CSA requires that the
.’’ The Attorney General has delegated
export, engage in research, conduct temporary control of these substances
scheduling authority under 21 U.S.C.
instructional activities or chemical expire two years from the effective date
811 to the Administrator of the DEA, 28
analysis, or possess), or propose to of the scheduling order, or on May 15,
CFR 0.100, who in turn has redelegated
handle UR-144, XLR11, or AKB48. 2015. 21 U.S.C. 811(h)(2). However, the
that authority to the Deputy
CSA also provides that the temporary
DATES: Effective: May 11, 2016. Administrator of the DEA, 28 CFR part
scheduling may be extended for up to
FOR FURTHER INFORMATION CONTACT: 0, appendix to subpart R.
one year during the pendency of
Barbara J. Boockholdt, Office of The CSA provides that proceedings
proceedings under 21 U.S.C. 811(a)(1).
Diversion Control, Drug Enforcement for the issuance, amendment, or repeal
Id. Accordingly, on May 14, 2015, the
Administration; Mailing Address: 8701 of the scheduling of any drug or other
DEA published a notice of proposed
Morrissette Drive, Springfield, Virginia substance may be initiated by the
rulemaking (NPRM) to permanently
22152; Telephone: (202) 598–6812. Attorney General (1) on her own
control UR-144, XLR11, and AKB48 in
motion; (2) at the request of the schedule I of the CSA. 80 FR 27611.
SUPPLEMENTARY INFORMATION:
Secretary of the Department of Health Specifically, the DEA proposed to add
Legal Authority and Human Services (HHS); 1 or (3) on these substances to 21 CFR 1308.11(g),
The Drug Enforcement 1 As set forth in a memorandum of understanding
cannabimimetic agents. On May 15,
Administration (DEA) implements and entered into by the Food and Drug Administration 2015, the DEA extended the temporary
enforces titles II and III of the (FDA) and the National Institute on Drug Abuse scheduling of UR-144, XLR11, and
Comprehensive Drug Abuse Prevention (NIDA), the FDA acts as the lead agency within the AKB48 by one year, until May 15, 2016.
and Control Act of 1970, as amended. 21 HHS in carrying out the Secretary’s scheduling 80 FR 27854. On March 22, 2016, the
jstallworth on DSK7TPTVN1PROD with RULES
responsibilities under the CSA, with the
U.S.C. 801–971. Titles II and III are concurrence of NIDA. 50 FR 9518, Mar. 8, 1985.
DEA published a corrected notice of
referred to as the ‘‘Controlled The Secretary of the HHS has delegated to the proposed rulemaking, proposing the
Substances Act’’ and the ‘‘Controlled Assistant Secretary for Health of the HHS the placement of these substances as
Substances Import and Export Act,’’ authority to make domestic drug scheduling hallucinogenic substances under 21 CFR
recommendations. 58 FR 35460, July 1, 1993.
respectively, and are collectively Accordingly, all subsequent references to
1308.11(d), and providing an
referred to as the ‘‘Controlled ‘‘Secretary’’ have been replaced with ‘‘Assistant opportunity to comment on this
Substances Act’’ or the ‘‘CSA’’ for the Secretary.’’ proposed change. 81 FR 15188.
VerDate Sep<11>2014 15:15 May 10, 2016 Jkt 238001 PO 00000 Frm 00032 Fmt 4700 Sfmt 4700 E:\FR\FM\11MYR1.SGM 11MYR1](https://thefederalregister.org/doc/81_FR_29233/page/1.svg)
methanone (5-
May 14, 2015. The proposed rule identifiers for the three substances.
fluoro-UR-144, XLR11), and N-(1-
provided an opportunity for interested Comment Regarding Methadone. One
adamantyl)-1-pentyl-1H-indazole-3-
persons to file a request for hearing in commenter stated that methadone is
carboxamide (APINACA, AKB48) have a
accordance with the DEA regulations on very dangerous to use, especially with
high potential for abuse that is
or before June 15, 2015. No requests for the consumption of alcohol.
comparable to other schedule I
such a hearing were received by the DEA Response: Methadone is a
substances such as delta-9-
DEA. The NPRM also provided an schedule II synthetic opioid and is not
opportunity for interested persons to affected by this rule. 2 UR-144, XLR11, and AKB48 were initially
submit written comments on the Request Not to Control UR-144, proposed to be scheduled under § 1308.11(g).
proposal on or before June 15, 2015. XLR11, and AKB48. One commenter However, they do not meet the structural
opposed controlling UR-144, XLR11, requirement for ‘‘cannabimimetic agents.’’
Comments Received
jstallworth on DSK7TPTVN1PROD with RULES
Consistent with the analysis set forth in the DEA’s
and AKB48 stating ‘‘there is no reason 8-factor analysis, on March 22, 2016, the DEA
The DEA received three comments on to have this law.’’ published a corrected notice of proposed
the proposed rule to control UR-144, DEA Response: As outlined in detail rulemaking, with opportunity for comment,
XLR11, and AKB48 in schedule I of the in the HHS and DEA eight-factor proposing the placement of these substances as
hallucinogenic substances under 21 CFR
CSA. One commenter stated that the analyses, there is substantial evidence to 1308.11(d). 81 FR 15188. The substances are being
‘‘longwinded and unnecessarily difficult support control of UR-144, XLR11, and placed under § 1308.11(d), hallucinogenic
names of the chemical substances AKB48 in schedule I of the CSA. substances, under this final rule.
VerDate Sep<11>2014 15:15 May 10, 2016 Jkt 238001 PO 00000 Frm 00033 Fmt 4700 Sfmt 4700 E:\FR\FM\11MYR1.SGM 11MYR1](https://thefederalregister.org/doc/81_FR_29233/page/2.svg)
methanone (5- accordance with 21 CFR part 1317, in procedures of 5 U.S.C. 553 to be
fluoro-UR-144, XLR11), and N-(1- addition to all other applicable federal, effective not less than 30 days after
adamantyl)-1-pentyl-1H-indazole-3- state, local, and tribal laws. publication of the proposed rule. 5
carboxamide (APINACA, AKB48) have 3. Security. UR-144, XLR11, and U.S.C. 553(d). However, the APA
no currently accepted medical use in AKB48 continue to be subject to provides three exceptions for when an
treatment in the United States; and schedule I security requirements and agency may make a rule effective sooner
(3) There is a lack of accepted safety must be handled and stored pursuant to than 30 days after publication,
for use of (1-pentyl-1H-indol-3- 21 U.S.C. 821, 823, and 871(b), and in including if the agency finds for good
yl)(2,2,3,3- accordance with 21 CFR 1301.71– cause why the rule should be effective
tetramethylcyclopropyl)methanone (UR- 1301.93. sooner and publishes those reasons with
144), [1-(5-fluoro-pentyl)-1H-indol-3- 4. Labeling and Packaging. All labels, the rule. 5 U.S.C. 553(d)(3). The DEA
yl](2,2,3,3- labeling, and packaging for commercial finds that there is good cause for this
tetramethylcyclopropyl)methanone (5- containers of UR-144, XLR11, and scheduling action to be immediately
fluoro-UR-144, XLR11) and N-(1- AKB48 must comply with 21 U.S.C. 825 effective upon publication. A delay in
adamantyl)-1-pentyl-1H-indazole-3- and 958(e), and be in accordance with the effective date is unnecessary and
carboxamide (APINACA, AKB48) under 21 CFR part 1302. contrary to the public interest. It is
medical supervision. unnecessary because UR-144, XLR11,
5. Quota. Only registered
Based on these findings, the and AKB48 are already controlled under
manufacturers are permitted to
Administrator of the DEA concludes 21 U.S.C. 811(h). Additionally, a delay
manufacture UR-144, XLR11, or AKB48
that (1-pentyl-1H-indol-3-yl)(2,2,3,3- in the effective date could potentially
in accordance with a quota assigned
tetramethylcyclopropyl)methanone (UR- temporarily eliminate these substances
pursuant to 21 U.S.C. 826 and in
144), [1-(5-fluoro-pentyl)-1H-indol-3- from being controlled, thereby resulting
accordance with 21 CFR part 1303.
yl](2,2,3,3- in an imminent hazard to the public
tetramethylcyclopropyl)methanone (5- 6. Inventory. Every DEA registrant safety. As noted above, the use of UR-
fluoro-UR-144, XLR11), and N-(1- required to keep records and who 144, XLR11, and/or AKB48 has been
adamantyl)-1-pentyl-1H-indazole-3- possesses any quantity of UR-144, linked to serious adverse effects
carboxamide (APINACA, AKB48) XLR11, or AKB48 is required to including vomiting, nausea, anxiety,
including their salts, isomers and salts maintain an inventory of all stocks of agitation, seizures, hallucinations,
of isomers, whenever the existence of UR-144, XLR11, and/or AKB48 on hand, tachycardia, and stroke, which require
such salts, isomers, and salts of isomers pursuant to 21 U.S.C. 827 and 958, and visits to emergency facilities. In
is possible, warrant control in schedule in accordance with 21 CFR 1304.03, addition to the serious adverse effects,
I of the CSA. 21 U.S.C. 812(b)(1). 1304.04, and 1304.11. the misuse and abuse of UR-144, XLR11,
7. Records and Reports. Every DEA and/or AKB48 has been shown to result
Requirements for Handling UR-144, registrant must maintain records and
XLR11, and AKB48 in death.
submit reports pursuant to 21 U.S.C.
UR-144, XLR11, and AKB48 are 827 and 958, and in accordance with 21 Executive Orders 12866 and 13563,
currently scheduled on a temporary CFR parts 1304, 1312, and 1317. Regulatory Planning and Review, and
basis in schedule I 3 and therefore Manufacturers and distributors must 13563, Improving Regulation and
continue to be subject to the regulatory submit reports regarding UR-144, Regulatory Review
controls and administrative, civil, and XLR11, and/or AKB48 to the In accordance with 21 U.S.C. 811(a),
criminal sanctions applicable to the Automation of Reports and this scheduling action is subject to
manufacture, distribution, reverse Consolidated Order System (ARCOS) formal rulemaking procedures done ‘‘on
distribution, importation, exportation, pursuant to 21 U.S.C. 827 and in the record after opportunity for a
engagement in research and conduct of accordance with 21 CFR 1304 and 1312. hearing,’’ which are conducted pursuant
instructional activities or chemical 8. Order Forms. Every DEA registrant to the provisions of 5 U.S.C. 556 and
analysis, and possession of schedule I who distributes UR-144, XLR11, and/or 557. The CSA sets forth the criteria for
controlled substances, including those AKB48 must continue to comply with scheduling a drug or other substance.
listed below. These controls will the order form requirements, pursuant Such actions are exempt from review by
continue on a permanent basis: to 21 U.S.C. 828 and 21 CFR part 1305. the Office of Management and Budget
1. Registration. Any person who 9. Importation and Exportation. All (OMB) pursuant to section 3(d)(1) of
handles (manufactures, distributes, importation and exportation of UR-144, Executive Order 12866 and the
reverse distributes, imports, exports, XLR11, and AKB48 must be in principles reaffirmed in Executive Order
engages in research, or conducts compliance with 21 U.S.C. 952, 953, 13563.
instructional activities or chemical 957, and 958, and in accordance with 21
analysis with, or possesses) UR-144, CFR part 1312. Executive Order 12988, Civil Justice
Reform
jstallworth on DSK7TPTVN1PROD with RULES
XLR11, or AKB48, or who desires to 10. Liability. Any activity involving
handle UR-144, XLR11, or AKB48 must UR-144, XLR11, or AKB48 not This regulation meets the applicable
be registered with the DEA to conduct authorized by, or in violation of, the standards set forth in sections 3(a) and
3 UR-144, XLR11, and AKB48 are currently
CSA or its implementing regulations 3(b)(2) of Executive Order 12988 to
subject to schedule I controls on a temporary basis,
continues to be unlawful, and may eliminate drafting errors and ambiguity,
pursuant to 21 U.S.C. 811(h). 80 FR 27854, May 15, subject the person to administrative, minimize litigation, provide a clear legal
2016. civil, and/or criminal sanctions. standard for affected conduct, and
VerDate Sep<11>2014 15:15 May 10, 2016 Jkt 238001 PO 00000 Frm 00034 Fmt 4700 Sfmt 4700 E:\FR\FM\11MYR1.SGM 11MYR1](https://thefederalregister.org/doc/81_FR_29233/page/3.svg)
methanone (5-fluoro-UR-144,
Executive Order 13175, Consultation Paperwork Reduction Act of 1995. 44
and Coordination With Indian Tribal XLR11) ...................................... (7011)
U.S.C. 3501–3521. This action would (50) N-(1-adamantyl)-1-pentyl-
Governments not impose recordkeeping or reporting 1H-indazole-3-carboxamide
This rule does not have tribal requirements on State or local (APINACA, AKB48) ................. (7048)
implications warranting the application governments, individuals, businesses, or * * * * *
of Executive Order 13175. It does not organizations. An agency may not
have substantial direct effects on one or conduct or sponsor, and a person is not Dated: May 6, 2016.
more Indian tribes, on the relationship required to respond to, a collection of Chuck Rosenberg,
between the Federal Government and information unless it displays a Acting Administrator.
Indian tribes, or on the distribution of currently valid OMB control number. [FR Doc. 2016–11204 Filed 5–10–16; 8:45 am]
power and responsibilities between the BILLING CODE 4410–09–P
Congressional Review Act
Federal Government and Indian tribes.
This rule is not a major rule as
Regulatory Flexibility Act defined by section 804 of the Small
The Administrator, in accordance Business Regulatory Enforcement DEPARTMENT OF HOMELAND
with the Regulatory Flexibility Act Fairness Act of 1996 (Congressional SECURITY
(RFA), 5 U.S.C. 601–602, has reviewed Review Act (CRA)). This rule will not
Coast Guard
this final rule and by approving it result in: ‘‘an annual effect on the
certifies that it will not have a economy of $100,000,000 or more; a
33 CFR Part 165
significant economic impact on a major increase in costs or prices for
substantial number of small entities. On consumers, individual industries, [Docket No. USCG–2016–0137]
May 16, 2013, the DEA published a final Federal, State, or local government
order amending 21 CFR 1308.11(h) to agencies, or geographic regions; or Safety Zone; Fourth of July Fireworks,
temporarily place these three synthetic significant adverse effects on City of Eureka, Humboldt Bay, Eureka,
cannabinoids into schedule I of the CSA competition, employment, investment, CA
pursuant to the temporary scheduling productivity, innovation, or on the
ability of U.S.-based companies to AGENCY: Coast Guard, DHS.
provisions of 21 U.S.C. 811(h). 78 FR
28735. On May 15, 2015, the DEA compete with foreign based companies ACTION: Notice of enforcement of
published a final order extending the in domestic and export markets.’’ regulation.
temporary placement of these However, pursuant to the CRA, the DEA
SUMMARY: The Coast Guard will enforce
substances in schedule I of the CSA for has submitted a copy of this final rule
the safety zone for the Fourth of July
up to one year pursuant to 21 U.S.C. to both Houses of Congress and to the
Fireworks, City of Eureka in the Captain
811(h)(2). 80 FR 27854. Accordingly, all Comptroller General.
of the Port, San Francisco area of
entities that currently handle or plan to List of Subjects in 21 CFR Part 1308 responsibility during the dates and
handle these synthetic cannabinoids are times noted below. This action is
estimated to have already established Administrative practice and
procedure, Drug traffic control, necessary to protect life and property of
and implemented the systems and the maritime public from the hazards
processes required to handle UR-144, Reporting and recordkeeping
requirements. associated with the fireworks display.
XLR11, and AKB48. Therefore, the DEA During the enforcement period,
anticipates that this rule will impose For the reasons set out above, 21 CFR
part 1308 is amended as follows: unauthorized persons or vessels are
minimal or no economic impact on prohibited from entering into, transiting
businesses that currently handle UR- through, or anchoring in the safety zone,
144, XLR11, or AKB48 for lawful PART 1308—SCHEDULES OF
CONTROLLED SUBSTANCES unless authorized by the Patrol
purposes. This estimate applies to Commander (PATCOM).
entities large and small. Accordingly, ■ 1. The authority citation for 21 CFR DATES: The regulations in 33 CFR
the DEA has concluded that this rule part 1308 continues to read as follows:
will not have a significant effect on a 165.1191, Table 1, Item number 3, will
jstallworth on DSK7TPTVN1PROD with RULES
substantial number of small entities. Authority: 21 U.S.C. 811, 812, 871(b), be enforced from 10 a.m. on July 3, 2016
unless otherwise noted. through 10:40 p.m. on July 4, 2016.
Unfunded Mandates Reform Act of 1995 FOR FURTHER INFORMATION CONTACT: If
■ 2. In § 1308.11:
On the basis of information contained ■ a. Add paragraphs (d) (48) through you have questions on this notice, call
in the ‘‘Regulatory Flexibility Act’’ (50); and or email Lieutenant Junior Grade
section above, the DEA has determined ■ b. Remove paragraphs (h)(1) through Christina Ramirez, Sector San Francisco
and certifies pursuant to the Unfunded (3) and redesignate paragraphs (h)(4) Waterways Safety Division, U.S. Coast
VerDate Sep<11>2014 15:15 May 10, 2016 Jkt 238001 PO 00000 Frm 00035 Fmt 4700 Sfmt 4700 E:\FR\FM\11MYR1.SGM 11MYR1](https://thefederalregister.org/doc/81_FR_29233/page/4.svg)
Document Created: 2016-05-11 01:11:40
Document Modified: 2016-05-11 01:11:40
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Rules and Regulations | |
| Action | Final rule. | |
| Dates | Effective: May 11, 2016. | |
| Contact | Barbara J. Boockholdt, Office of | |
| FR Citation | 81 FR 29142 | |
| CFR Associated | Administrative Practice and Procedure; Drug Traffic Control and Reporting and Recordkeeping Requirements |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR